A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Deucravacitinib (Primary) ; Ustekinumab
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 15 Jun 2024 Results of this study presented at the 25th Annual Congress of the European League Against Rheumatism
- 15 Jun 2024 Results assessing characterize the efficacy of deucravacitinib by sex on clinical assessments and PROs in patients with PsA presented at the 25th Annual Congress of the European League Against Rheumatism
- 15 Nov 2023 Results assessing the effect of deucravacitinib on pain across different instruments presented at the ACR Convergence 2023.